BMS-986166
- Generic Name
- BMS-986166
A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT05409157
- Locations
- 🇺🇸
Local Institution - 0001, Madison, Wisconsin, United States
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT05014438
- Locations
- 🇩🇪
Private Practice - Dr. Ralph von Kiedrowski, Selters, Germany
🇺🇸Local Institution - 0008, Skokie, Illinois, United States
🇺🇸Local Institution - 0078, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT04965402
- Locations
- 🇺🇸
West Coast Clinical Trials Global, Cypress, California, United States
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04956627
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT04934696
- Locations
- 🇺🇸
West Coast Clinical Trials Global, Cypress, California, United States
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Other: Placebo matching BMS-986166
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 213
- Registration Number
- NCT03038711
- Locations
- 🇺🇸
PPD Development, LLC, Austin, Texas, United States
A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 66
- Registration Number
- NCT02790125
- Locations
- 🇺🇸
PPD Development, LLC, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath